CirculatingTP53mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

Volume: 13, Pages: 175883592110337 - 175883592110337
Published: Jan 1, 2021
Abstract
Background: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression during FOLFIRINOX chemotherapy, and overall survival (OS). Methods: Circulating cell-free DNA was analyzed with a 57 gene next-generation sequencing panel using plasma samples of 48 PDAC...
Paper Details
Title
CirculatingTP53mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
Published Date
Jan 1, 2021
Volume
13
Pages
175883592110337 - 175883592110337
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.